Pamidronate administration improves the secondary hyperparathyroidism due to 'bone hunger syndrome' in a patient with osteoblastic metastases from prostate cancer

Prostate

Volumn 33, Issue 4, 1997, Pages 252-255

  Berruti, Alfredo ^a   Sperone, Paola ^a   Fasolis, Giuseppe ^b   Torta, Mirella ^a   Fontana, Dario ^b   Dogliotti, Luigi ^a,c   Angeli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Azienda Ospedaliera Universitaria S Luigi   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Bone Hunger Syndrome; Bone metastases; Pamidronate; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN DERIVATIVE; PAMIDRONIC ACID;

AGED; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER PATIENT; CASE REPORT; COLLAGEN DEGRADATION; DRUG EFFECT; HUMAN; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; SECONDARY HYPERPARATHYROIDISM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030832980     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971201)33:4<252::AID-PROS5>3.0.CO;2-J     Document Type: Article

References (15)

1. Galasko, CSB: Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976;263:507-508.
2. Urwin GH, Percival RC, Harris S, Beneton MNC, Williams JL, Kanis JA: Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721-723.
3. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran MD, Edouard CM, Eng BS, Meunier PJ: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983;51:918-924.
4. Burki F, Coindre JM, Mauriac L: Sclerotic bone metastases of prostatic origin and osteomalacia. Importance of a histomorphometry study. In "Prostate Cancer, Part A: Research, Endocrine Treatment and Histopathology." New York: Alan R. Liss, Inc., 1987, pp 560-571.
5. Rico H, Uson A, Hernandez ER, Pradas P, Paramo P, Cabranes JA: Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. Eur Urol 1990;17:35-39.
6. Berruti A, Piovesan A, Torta M, Gorzegno G, Paccotti P, Dogliotti L, Angeli A: Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996; 73:1581-1587.
7. Minisola S, Perugia G, Scarda A, Scarnecchia L, Tuzzolo D, Rossi W, Mazzuoli G: Biochemical picture accompanying sclerotic bone metastases of prostatic origin. Br J Urol 1987;60:443-446.
8. Douglas DL, Duckworth T, Russel GG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS: Effect of dichloromethylene diphosphonate in Paget's disease of bone and hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1043-1071.
9. Coleman RE: Evaluation of bone disease in breast cancer. Breast 1994;3:73-78.
10. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT: Comparison of three intravenous bisphosphonates in cancer associated hypercalcemia. Lancet 1989;18: 1180-1182.
11. Clarke NW, Holbrook IB, McClure J, George NJR: Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br J Cancer 1991;63:420-423.
12. Purhoit OP, Dickinson I, Coleman RE: Effect of a single high dose treatment with pamidronate on markers of bone resorption in patients with bone metastases [abstr]. Br J Cancer 1994; 69(Suppl 21):45.
13. Stronski S, Betteschen-Camin L, Wetterwald A, Felix R, Frechsee V, Fleisch H: Bisphosphonates inhibit 1.25 dihydroxy vit D3 induced increase of osteocalcin in plasma rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 1988; 42:248-254.
14. Coleman RE, Purohit OP: Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993;19:79-103.
15. Azria M: The value of biomarkers in detecting alterations in bone metabolism. Calcif Tissue Int 1989;45:7-11.